T he management of patients with acute coronary syndrome (ACS), including unstable angina, non-ST segment elevation myocardial infarction (non-STEMI), and ST segment elevation myocardial infarction (STEMI), continues to be a challenge for the health care industry. Despite numerous health care advances, ACS remains a major source of both morbidity and mortality. In 2005, there were approximately 772,000 patients with ACS discharged from hospitals in the United States. 1 Further, myocardial infarction (MI) was the primary cause of death for nearly 157,000 Americans in 2004 and a contributing cause of death for approximately 40,000 additional persons. 1 In addition to primary prevention efforts, joint guidelines by the American College of Cardiology (ACC) and the American Heart Association (AHA) suggest secondary drug prevention measures to be used in patients with ACS. 2, 3 In conjunction with diet and lifestyle modifications, these guidelines suggest the use of statin, beta-blocker, and renin-angiotensin aldosterone system inhibitor drug therapies in ACS patients. 2, 3 Unfortunately, the benefits of these drug therapies can be realized only if they are routinely used in clinical practice. Adoption and maintenance of such therapies requires commitment by patients, providers, and the health care system.
The article by Lee et al. in this issue of JMCP estimates compliance with ACC/AHA-recommended treatments, including statins, beta-blockers, and angiotensin-converting enzyme (ACE) inhibitors/angiotensin II receptor blockers (ARBs), following ACS hospitalizations. 4 Lee et al. used pharmacy and medical insurance claims data for patients admitted to the hospital for ACS (from July 2003 through June 2004) and concluded that post-discharge secondary prevention was suboptimal, especially when evaluating the percentage of patients prescribed all 3 medication classes concomitantly. 4 Further, the authors concluded that treatment rates varied by age (i.e., patients aged ≥ 80 years were less likely to receive any of the therapies), gender (i.e., women were less likely than men to receive statins), and specific diagnoses (i.e., patients with intermediate coronary syndrome were less likely than patients with MI to receive any of the study medications). As managed care pharmacists, providers, and administrators seek to improve the quality of care for their patient populations, these findings suggest that secondary drug therapy following a hospitalization for ACS is one potential area for improvement. Although largely descriptive, the study provides insight into the treatment patterns of a real-world population of persons with a recent coronary event, and the authors are to be commended for publishing these data.
Despite the relevance and timeliness of these findings, it is important to highlight and discuss several important limitations of these analyses (measurement issues) that should be considered alongside the results of this study. In addition, Lee et al.'s work also serves as a springboard for a larger discussion of several prominent opportunities for managed care. indicative of a hospitalization for ACS. For these purposes, the authors evaluated the primary diagnosis and up to 9 supporting diagnoses associated with the hospitalization claim. As in any claims-based study, a key question is the degree to which formal diagnoses accurately identified the target population. A 2004 validation study published by Rosamond et al. evaluated the validity of hospital discharge codes as an identification method for cardiac events by comparing hospital codes with the Atherosclerosis Risk in Communities (ARIC) identification criteria. 5 This study found that 75% of persons identified via ICD-9-CM code 410 had a "definite" or "probable" MI according to the more rigorous ARIC classification scheme. When evaluating ICD-9-CM code 411.xx, only 14% of patients met the ARIC definition for "definite" or "probable" MI. (i.e., prescription drug coverage caps among some Medicare beneficiaries during the study period). 4 These issues are well known to those using medical claims data for research purposes 6 and highlight the importance of careful interpretation of these and other results derived solely from health care claims databases. In the absence of conducting a more thorough chart review or interviewing patients (or physicians) directly, a more transparent presentation of these limitations, including sensitivity analyses to produce estimates of potential bias, would be helpful.
Measurement Issues
As an example, an estimated 32% of the 492 Medicare-eligible members in Lee et al.'s study sample (about 14% of the sample overall) were enrolled in a senior pharmacy benefits program that provided coverage up to $1,100 annually, with discounts on purchases over the $1,100 benefit maximum. Although the authors expressed a belief that the prescription price discounts were a sufficient incentive to encourage submission of pharmacy claims through the senior program, thereby ensuring complete claims capture, sensitivity analyses would have provided more definitive estimates of the effect of including this group in the study sample. Prevalence estimates, including the elderly beneficiaries known to have capped coverage, could have been compared with prevalence estimates obtained after excluding these study subjects. Such an analysis would have provided valuable insight into the robustness of these estimates and the degree to which this bias may be operating. In addition, a simpler approach would be to compare overall drug utilization (of all medications, not just those under study) across the elderly study subjects with full versus capped coverage or to compare utilization with some external benchmark, such as pharmaceutical usage in the Current Medicare Beneficiary Survey (CMBS). 7 If the estimates in these populations were similar, the reader might infer that the capped prescription drug coverage among a portion of the elderly beneficiaries is potentially not influencing the estimated treatment effects.
Lee et al. raise the possibility that patients may have been prescribed appropriate therapy but failed to fill the prescriptions. Previous research on the propensity for patients to fill prescriptions post MI is consistent with this view. A recent study performed in Canada by Jackevicius et al. (2008) found that post-MI patients were more likely to fill prescriptions for cardiac medications than for noncardiac medications (82% vs. 35%, respectively) within 4 months of hospital discharge. In addition, in that study, most (73%) of all medications prescribed were filled within 7 days of hospital discharge. 8 An additional study conducted in the U.S. by Butler et al. pound that 80% of patients discharged from the hospital post MI with a beta-blocker prescription filled that prescription (as evidenced by pharmacy claims) in the 30 days following hospital discharge. 9 Despite the inherent limitations of estimating the prevalence of secondary preventive treatments among patients with ACS, using claims databases, the Lee et al. study 4 supports other studies demonstrating suboptimal treatment rates with secondary pharmacological agents in the management of ACS. [10] [11] [12] [13] For example, Ye et al.'s claims database study found that only 47.8% of patients not taking a statin in the 6 months prior to hospitalization for coronary heart disease (CHD) filled a statin prescription within 6 months of hospital discharge. 13 Ye et al.'s finding is similar to the statin treatment rate of 45.0% calculated by Lee et al. for patients without statin treatment in the 6 months prior to ACS hospitalization. Although the Lee et al. study is not without bias, it is unlikely that biases accounted fully for the large gap in treatment. Despite the success of numerous quality improvement initiatives conducted by managed care organizations over the last 3 decades, collectively the results from these studies demonstrate that there is room for improvement in the management of ACS. Thus, system-level factors may be necessary to promote more effective use of these agents.
Managed Care Opportunities
In spring 2007, the National Committee for Quality Assurance (NCQA) proposed retirement of the Beta-blocker Treatment after a Heart Attack (BBH) measure collected as part of the Healthcare Effectiveness Data and Information Set (HEDIS) measures. 14 NCQA cited several important reasons for considering the retirement of this measure: health plans consistently performed well on the measure (>90%); there was little variation between plans; and the measure was administratively complex, placing a high burden on health plans for its completion. After careful consideration, the measure was retired starting in the 2008 measurement year. An additional measure, the Persistence of Beta-blocker Treatment after a Heart Attack, will remain and assess the percentage of patients with an MI during the measurement year who were taking a beta-blocker for 180 days following the event. In an editorial in this issue of JMCP, Curtiss examines the apparent discrepancy between Lee et al.'s findings and the high rate of compliance observed by the NCQA, noting that the HEDIS measurement algorithm for BBH excludes patients with numerous comorbidities, including insulin-dependent diabetes mellitus, asthma, heart block greater than first degree, sinus bradycardia, congestive heart failure, left ventricular dysfunction, and chronic obstructive pulmonary disease. 15 We can assume that quality prescribing post MI is a moving target that is not simply captured through a 1-faceted measurement. Because HEDIS measures are potentially effective in promoting quality use of medications, a future, more comprehensive measure assessing the use of beta-blockers, ACE inhibitors/ARBs, and statins may be warranted.
Another important opportunity arises from the current lack of guidelines applicable to the elderly population. Lee et al. found that patients aged ≥ 65 years were less likely to receive statins or beta-blockers compared with their relatively younger counterparts (aged 45 to 64 years). 4 In addition, they reported that patients aged ≥ 80 years were less likely to receive ACE inhibitors or ARBs than patients aged 45 to 64 years. Within the area of secondary prevention in patients with unstable angina, non-STEMI, and STEMI, the ACC/AHA guidelines provide clear recommendations on the use of secondary prevention agents, such as beta-blockers and statins, yet evidence supporting these and other guidelines relies heavily on the results of randomized clinical trials (RCTs). Although RCTs are esteemed as the gold standard for internal validity, their generalizability to elderly patients is often limited. RCTs often either exclude older study participants altogether or limit samples to highly selected populations (e.g., lacking comorbidities common among the elderly). 16 As ACS commonly occurs with advanced age, suboptimal treatment rates in the secondary prevention of ACS may, in part, be due to lack of evidence of the risks and benefits of these treatments within the target population. Therefore, it is important that researchers, clinicians, and decision makers support the expansion of clinical studies to the elderly and consider the nuances of this population when making treatment recommendations.
Lastly, a recent movement within the health care industry is the introduction of pay-for-performance (P4P) measures that reward physicians through reimbursement increases and incentives based on predefined quality measures. In 2006, a survey conducted by Rosenthal et al. asked more than 250 health maintenance organizations (HMOs) if their contracts contained P4P. 17 Rosenthal et al. found that 126 of 252 HMOs utilized some P4P measures, with 90% of these plans having at least 1 program geared toward physicians. A recent study by Cutler et al. evaluated diabetes control in a P4P program instituted in California aimed at promoting quality care in diabetic patients. 18 In that study, the researchers found that the rate of low-density lipid cholesterol testing was higher in patients enrolled in a diabetes care program than in the control group (91.5% vs. 67.8%, respectively). As undertreatment of chronic conditions including ACS persists, we must consider the appropriateness of P4P measures as a means to promote quality prescribing. Will this method of reimbursement stand the test of time and improve the appropriate prescribing of medications for important chronic diseases? Only time can tell.
In conclusion, despite methodological limitations of the Lee et al. study, undertreatment of ACS is probable. After decades of research identifying suboptimal treatment, it is important that we begin to take steps to correct these deficiencies and realize the benefits of optimal treatment within the population of ACS survivors. Three potential managed care opportunities for improving the secondary treatment of ACS include the introduction of new multifaceted HEDIS measures, the further expansion of guidelines, and RCTs to be inclusive of the elderly population and the evaluation of the merits of incentivizing physicians through P4P measures.
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